Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +0.10%81 EBITDA Margin % is 14.38% as of Mar. 2026, which is 8% above its 10-year median of 13.37. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Orion Infusions ranks better than 56.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Orion Infusions's EBITDA for the
three
months ended in Mar. 2026 was BDT12.0 Mil. Orion Infusions's Revenue for the
three
months ended in Mar. 2026 was BDT83.6 Mil. Therefore, Orion Infusions's EBITDA margin for the quarter that ended in Mar. 2026 was 14.38%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Orion Infusions EBITDA Margin % Related Terms
Orion Infusions EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Orion Infusions's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Orion Infusions's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a EBITDA Margin % of 14.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orion Infusions and its competitors. This is near median its historical median of 13.37. Over the past decade, Orion Infusions' EBITDA Margin % has ranged from 11.51 to 15.71. According to the industry distribution chart, Orion Infusions ranks #419 out of 961 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Orion Infusions' EBITDA Margin % too high?
Orion Infusions' current EBITDA Margin % of 14.38% is near median its 10-year median of 13.37. Over the past 10 years, this metric has ranged from a low of 11.51 to a high of 15.71. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Orion Infusions' value of 14.38% is 15.1% above this industry median. Based on the distribution chart, Orion Infusions ranks #419 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #419 out of 961 companies for EBITDA Margin %. This puts Orion Infusions in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Orion Infusions' value of 14.38% is 15.1% above this benchmark. Historically, Orion Infusions' own EBITDA Margin % has ranged from 11.51 to 15.71 over the past decade. While the company's 10-year median is 13.37 vs. the industry median of 12.49, Orion Infusions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current EBITDA Margin % of 14.38% is 15.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current EBITDA Margin % is 14.38%, which is near median its own 10-year median of 13.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current EBITDA Margin % is 14.38%, which is near median its 10-year median of 13.37 and 15.1% above the Drug Manufacturers industry median of 12.49. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current EBITDA Margin % is 14.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
EBITDA Margin %: 14.38% (near median its 10-year median of 13.37)
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
Industry Position: 15.1% above the Drug Manufacturers median (#419 of 961)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
